United Health Products (UEEC) Q2 2025 earnings summary

Executive summary

• Continued focus on obtaining FDA Class III PMA for CelluSTAT hemostatic gauze, pausing commercial activities to prioritize regulatory approval.

• No revenue generated in Q2 2025 or YTD due to resource allocation toward regulatory efforts.

• Net loss for Q2 2025 was $315,187, an improvement from $432,021 in Q2 2024, driven by lower operating expenses.

• Net loss for the six months ended June 30, 2025 was $1,846,846, up from $883,959 in the prior year period, mainly due to increased stock-based compensation.

Financial highlights

• Operating expenses for Q2 2025 were $268,356, down from $405,177 in Q2 2024, primarily due to reduced legal/professional fees and inventory write-offs.

• Operating expenses for the six months ended June 30, 2025 were $1,757,572, up from $830,271, mainly due to $1,120,125 in stock-based compensation.

• Cash on hand at June 30, 2025 was $225, down from $168,883 at December 31, 2024.

• Negative working capital of $1,883,479 as of June 30, 2025.

• Net cash used in operating activities for the six months ended June 30, 2025 was $458,658.

Outlook and guidance

• Uncertainty remains regarding the timing and outcome of FDA PMA approval for CelluSTAT.

• Company evaluating strategic options, including sale, merger, or commercial partnerships, pending regulatory outcome.

• No assurance of future financing or ability to continue as a going concern.